Trending...
- The Anderson Periodontal Wellness Office Now Uses Zirconia Dental Implants to Restore Smiles!
- Orbex to Exhibit as Diamond Sponsor at the Fintech & Crypto Summit Bahrain, 2023
- Zilker Partners Expands Recruiting and Digital Marketing Services to Keep Pace with Changing Business Climate
RARITAN, N.J.--(BUSINESS WIRE)--NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
No intention to bid statement for Horizon Therapeutics plc ("Horizon")
Further to the announcement by Horizon on November 29, 2022, Janssen Global Services, LLC ("the Company") confirmed today that it does not intend to make an offer for Horizon. Accordingly, the Company will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules. The Company reserves the right within the next 6 months to set aside this statement where so permitted under Rule 2.8 (including Rule 2.8(c)(ii)).
This announcement is intended to be treated as a statement to which Rule 2.8 of the Irish Takeover Rules applies.
Irish Takeover Rules
The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
This announcement is not intended to, and does not, constitute or form part of (i) an offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities; (ii) the solicitation of an offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities; or (iii) the solicitation of any vote or approval in any jurisdiction, pursuant to this announcement or otherwise.
More on Jersey Desk
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
More on Jersey Desk
Contacts
Media Contact:
Michelle Romano
mromano3@its.jnj.com
Investor Relations:
Jessica Moore
RA-JJCUS-InvestorRel@ITS.JNJ.com
No intention to bid statement for Horizon Therapeutics plc ("Horizon")
Further to the announcement by Horizon on November 29, 2022, Janssen Global Services, LLC ("the Company") confirmed today that it does not intend to make an offer for Horizon. Accordingly, the Company will be bound by the restrictions set out in Rule 2.8 of the Irish Takeover Rules. The Company reserves the right within the next 6 months to set aside this statement where so permitted under Rule 2.8 (including Rule 2.8(c)(ii)).
This announcement is intended to be treated as a statement to which Rule 2.8 of the Irish Takeover Rules applies.
Irish Takeover Rules
The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
This announcement is not intended to, and does not, constitute or form part of (i) an offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities; (ii) the solicitation of an offer or invitation to purchase or otherwise acquire, subscribe for, tender, exchange, sell or otherwise dispose of any securities; or (iii) the solicitation of any vote or approval in any jurisdiction, pursuant to this announcement or otherwise.
More on Jersey Desk
- Vanpowers Bike LEGO-Like Assembled-Frame Ebike City Vanture Receives TÜV SÜD Certification
- Louisville Riverport Authority Applies To Include South Central Kentucky In Foreign Trade Zone #29 Service Area
- Transform Your Life with Anna D. Banks: Adopting a Growth Mindset & Continuous Learning
- Summer Art Camps Registration Underway at The Center for Contemporary Art
- IntellaTriage Hires New Director of Clinical Operations
About the Janssen Pharmaceutical Companies of Johnson & Johnson
At Janssen, we're creating a future where disease is a thing of the past. We're the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2022, including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.
More on Jersey Desk
- Phase IIb Clinical Study of Investigational Compound Elinzanetant Evaluated Efficacy and Safety in Postmenopausal Patients with Vasomotor Symptoms Study Findings Published in Menopause: The Journal of The North American Menopause Society
- Gymboree Announces 2023 Brand Ambassador, Mandy Moore, and Launches New Spring Campaign
- Metro Commercial brokers deal for BJ's Wholesale Club in West Palm Beach, FL
- L-Strategies political and business consulting firm launched by partners Angie Wong and Jared Craig with Donna and Stan Fitzgerald
- Zilker Partners Expands Recruiting and Digital Marketing Services to Keep Pace with Changing Business Climate
Contacts
Media Contact:
Michelle Romano
mromano3@its.jnj.com
Investor Relations:
Jessica Moore
RA-JJCUS-InvestorRel@ITS.JNJ.com
Filed Under: Business
0 Comments
Latest on Jersey Desk
- UMe Celebrates Songwriter PAUL JABARA's Birthday With Newly Remastered Version of Casablanca 's Paul Jabara's Greatest Hits…and Misses
- Fintech Startup BeFiSc Launches AI/ML Powered KYC Solutions Beyond Financial Scores
- Bob Holz New Video with Darryl Jones of the Rolling Stones, Concert, Album and Endorsement
- Rowan University Student Named New Jersey's Top Student Entrepreneur by EO Global Student Entrepreneur Awards
- VSA Prospecting Launches New Website, Enhancing the User Experience
- Yida Gao and Shima Capital Celebrate Portfolio Company's Successful NFT Sellout
- "Murdaugh Murders Podcast" Launches Spinoff "Cup of Justice" and Skyrockets to Apple's #1 Podcast
- CPAC 2023 Congressional Candidate Forum Meet and Greet March 2nd at the historic University Club in DC
- IoT Observatory to host Plenary Session at 2023 InsurTech Hartford Symposium
- Art After Hours Valentine's Day Paint & Sip at The Center for Contemporary Art
- American Water Included in 2023 Bloomberg Gender-Equality Index for Fifth Consecutive Year
- PASTARAMEN TO OPEN FIRST BRICK-AND-MORTAR LOCATION
- Eliza Neals "Candy Store" new spring single out February 14th Valentines Day 2023!
- The Case For Bonds As Part Of A Portfolio
- Vision Research Supplies Embedded Phantom High-Speed Camera for Use With FDA-Cleared Sepsis Test
- Dr. David Basar Now Uses The 3Shape TRIOS® Digital Scanner At His Advanced Smile Dentistry Office!
- TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
- Cardinal Analytics Launches on the Bloomberg App Portal
- 24th Annual Super Bowl Soulful Celebration Returns On Feb. 8 With Patti LaBelle, Israel Houghton & The Players Choir, Honoring NFL QB Jalen Hurts
- Orbex to Exhibit as Diamond Sponsor at the Fintech & Crypto Summit Bahrain, 2023